Capricor Therapeutics (CAPR) Stock Price, Quote, News & History | Benzinga

Capricor Therapeutics Inc (CAPR) Stock Price, Quote, News & History

CAPRNASDAQ

Trade with Public

Trade with Public

$7.98

0.9012.71%

At close: Aug 19, 5:00 PM EST

$7.90

-0.08-1%

After Hours: 5:29 PM EST

Earnings: Q2 2026 Earnings were released on Thu Aug 13th, after the market close

Conference Call: The most recent conference call started at 4:30 PM, 6 days ago

Click to view the webcast

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$7.19

Close

$7.98

Volume / Avg.

8.43M / 4.55M

Day Range

$7.14 - $7.99

52 Wk Range

2.96 - 40.37

Market Cap

$459.30M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

39

Short Interest

30.35%

Days to Cover

2.06

Recent Capricor Therapeutics, Inc. News

H World Group Posts Upbeat Q2 Results, Joins Almonty Industries, Diana Shipping And Other Big Stocks Moving Higher On Monday

H World Group (HTHT) beats earnings and raises sales guidance, shares jump 8.1%. Other big gainers include ANGX, ARGX, and MESO.

Avi Kapoor

Capricor Therapeutics Remains Optimistic about Deramiocel FDA Approval

Capricor Therapeutics highlights Deramiocel's FDA review, commercial readiness, and cash position of $approximately $237.9 million.

Vandana Singh

This Capricor Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday

Wall Street analysts revised their ratings for top stocks. Visit benzinga.com/analyst-stock-ratings for all changes, including upgrades and downgrades.

Avi Kapoor

Why Eton Pharmaceuticals Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket

Eton Pharmaceuticals Inc (NASDAQ: ETON) rose in pre-market trading after reporting strong Q2 results and issuing FY26 revenue guidance above estimates.

Avi Kapoor

Capricor Therapeutics (CAPR) Shares Soar Over 67% After Hours: Here's Why

Capricor Therapeutics shares surged 67.22% after hours following quarterly results and an update on the FDA review of its application.

Mohd Haider

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-104.00M

Investing Cash Flow (TTM)

-144.36M

Financing Cash Flow (TTM)

246.05M

Free Cash Flow (TTM)

-129.78M

Capital Expenditure (TTM)

-25.78M

Net Change in Cash (TTM)

-2.31M

Analyst Trends and Forecast

4

Mar

1

May

3

Jul

1

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.0

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$265.32M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

1.67

Earnings Yield % (TTM)

-34.56%

Earnings Yield % (FWD)

-32.02%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$4.24

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$20.94M

Debt to Equity

0.37

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$7.19

Close

$7.98

Volume / Avg.

8.43M / 4.55M

Day Range

$7.14 - $7.99

52 Wk Range

2.96 - 40.37

Market Cap

$459.30M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

39

Short Interest

30.35%

Days to Cover

2.06

About

Sector

Health Care

Industry

Biotechnology

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in mu...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Capricor Therapeutics (CAPR) stock?

A

You can purchase shares of Capricor Therapeutics (NASDAQ:CAPR) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Capricor Therapeutics (CAPR) competitors?

A

Other companies in Capricor Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for Capricor Therapeutics (CAPR) stock?

A

Capricor Therapeutics has a consensus price target of $33.57.

Q

What is the current price for Capricor Therapeutics (CAPR)?

A

The stock price for Capricor Therapeutics (NASDAQ: CAPR) is $7.9 last updated August 19, 2026 at 5:29 PM EDT.

Q

Does Capricor Therapeutics (CAPR) pay a dividend?

A

There are no upcoming dividends for Capricor Therapeutics.

Q

When is Capricor Therapeutics (NASDAQ:CAPR) reporting earnings?

A

Capricor Therapeutics does not have any upcoming earnings scheduled.

Q

Is Capricor Therapeutics (CAPR) going to split?

A

There is no upcoming split for Capricor Therapeutics.

Q

What sector and industry does Capricor Therapeutics (CAPR) operate in?

A

Capricor Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.